aTyr Pharma announced plans to continue developing efzofitimod for pulmonary sarcoidosis after a positive FDA Type C meeting. The company will submit an IND in June 2026 for a new global Phase 3 trial focusing on patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The trial will use forced vital capacity (FVC) as the primary endpoint and the King's Sarcoidosis Questionnaire (KSQ-Lung) as a key secondary endpoint, reflecting FDA guidance. The study aims to enroll about 372 patients and increase dosing frequency to enhance efficacy while maintaining safety. This development offers hope for improved treatment options in a disease with limited therapies.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
